Event Date/Time: Dec 01, 2008
January 2008 markedthe 25th anniversary of the Orphan Drug Act which gives companies tax incentives and seven years of market exclusivity in return for developing treatments for rare diseases. According to the FDA, in the decade before the act passed there were fewer than 10 products approved for orphan diseases; today, there are over 300. Building off of our past two successful events, CBIis proud to announce theThirdAnnual Rare Disease Leadership Summitwhich brings together industry stakeholders and key thought leaders in the rare disease and orphan drug development arena. Panel discussions and case studies areheard covering financial, clinical, marketing and reimbursement considerations for successful orphan drug development.
Topics being researched for 2008 include:
â€¢ Patient segmentation in defining orphan drug population
â€¢ Strategies in obtaining grant funding for rare disease drug development
â€¢ Orphan drug designation approval process and incentives for development
â€¢ Novel protein therapeutics for rare diseases
â€¢ Global pricing, reimbursement and post- marketing strategies for orphan drugs